Screener
Monte Rosa Therapeutics, Inc. GLUE Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s restricted cash?
- Monte Rosa Therapeutics, Inc. (GLUE) reported restricted cash of $4.94M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s restricted cash changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s restricted cash decreased by 0.2% year-over-year, from $4.95M to $4.94M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s restricted cash has grown at a 33.6% compound annual growth rate (CAGR), from $1.16M to $4.95M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Monte Rosa Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude